AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended):** A pharmaceutical liquid composition comprising a pyridone derivative represented by the following formula (I):



wherein R^1 is an alkyl group optionally having a substituent selected from the group consisting of a C_{1-6} lower alkyl group optionally substituted at any of the 3-, 4- or 5-position with a halogen atom, a carboxyl group, an alkoxycarbonyl group, and an amino group and R^2 is a phenyl group optionally having a substituent selected from the group consisting of a C_{1-6} lower alkyl group, a halogen atom, a carboxyl group, an alkoxycarbonyl group or an amino group, or a pharmaceutically acceptable salt thereof, and a solvent capable of dissolving said pyridone derivative in a concentration of ~~about~~ 10% to about 25% by weight.

2. **(previously presented):** A pharmaceutical liquid composition according to Claim 1, wherein the pyridone derivative is a 5-methyl-1-phenyl-2-(1H)-pyridone (Pirfenidone) wherein R^1 is a methyl group at the 5-position and R^2 is a phenyl group in the formula (I) or a pharmaceutically acceptable salt thereof.

3. (previously presented): A pharmaceutical liquid composition according to Claim 1, wherein the solvent is a diethylene glycol monoethyl ether.

4. (original): A pharmaceutical liquid composition according to Claim 3, wherein the diethylene glycol monoethyl ether has a purity of 99% or higher.

5. (previously presented): A pharmaceutical liquid composition according to Claim 1, further comprising a concentrating agent.

6. (previously presented): A pharmaceutical liquid composition according to Claim 1, further containing an antioxidant.

7. (original): A pharmaceutical liquid composition according to Claim 6, wherein the antioxidant is an α-tocopherol.

8. (previously presented): A pharmaceutical liquid composition according to Claim 1, in the form of an oral, percutaneous, nasal or vaginal preparation or in the form of a spray, patch, inhalant, injection or intravenous drip.

9. (currently amended): A pharmaceutical liquid composition according to Claim 1, having the following components:

Ingredients	% by weight
Pirfenidone	~~1-25~~10-25
Diethylene glycol monoethyl ether	70-80
Ethanol (95%)	0-10

Polyvinyl pyrrolidone or hydroxypropyl cellulose	0-3
Sodium metabisulfite	0.02-2
Methyl or propyl paraben	0-0.5
Purified water	0-25 .

10. (previously presented): A pharmaceutical liquid composition according to Claim 1, having the following components:

Ingredients	% by weight
Pirfenidone	10-25
Diethylene glycol monoethyl ether	75-80
Purified water	0-10 .

11. (previously presented): A pharmaceutical liquid composition according to Claim 18, having the following components:

Ingredients	% by weight
Pirfenidone	10-25
Diethylene glycol monoethyl ether	75-80
α-Tocopherol	0.1-0.5
Hydroxypropyl cellulose	0-3
Purified water	0-10 .